Taiwan-based GlycoNex, Inc. (TPEx: 4168) has announced a licensing agreement with an undisclosed company for its SPD8, a biosimilar version of Amgen’s (NASDAQ: AMGN) Prolia and Xgeva (denosumab). The agreement involves an undisclosed amount of development and commercialization milestone payments, granting the licensee rights to develop, secure regulatory approval for, and commercialize SPD8 in the designated market.
Development and Indications
SPD8 is designed to treat osteoporosis and giant cell tumor of bone. The drug initiated its Phase III study in December of last year, with the first patient enrolled. This marks a significant step forward in the development of SPD8, as it moves closer to potential regulatory approval and commercialization.
Significance of the Agreement
The licensing agreement underscores GlycoNex’s commitment to advancing its biosimilar pipeline and expanding its market reach. By partnering with an undisclosed company, GlycoNex aims to leverage the licensee’s expertise and resources to expedite the development and commercialization of SPD8, ultimately bringing a cost-effective treatment option to patients in need.-Fineline Info & Tech
